DOI: 10.1517/14656566.6.8.1421. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration

Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration

10.1517/14656566.6.8.1421

Crossref journal-article

Informa Healthcare

Expert Opinion on Pharmacotherapy (3197)

Bibliography

Doggrell, S. A. (2005). Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert Opinion on Pharmacotherapy, 6(8), 1421â1423.

Authors 1

Sheila A Doggrell (first)

References 5 Referenced 69

10.1001/jama.293.12.1509 / JAMA by VAN WIJINGARDEN P (2005)
10.1074/jbc.273.32.20556 / J. Biol. Chem. by RUCKMAN J (1998)
{'key': 'CIT0003', 'first-page': '2805', 'volume': '351', 'author': 'GRAGOUNDAS ES', 'year': '2004', 'journal-title': 'Pegaptanib for neovascular age-related macular degeneration. N Engl. J. Med.'} / Pegaptanib for neovascular age-related macular degeneration. N Engl. J. Med. by GRAGOUNDAS ES (2004)
{'key': 'CIT0004', 'first-page': '2621', 'volume': '5', 'author': 'DOGGRELL SA', 'year': '2004', 'journal-title': 'Pharmacother.'} / Pharmacother. by DOGGRELL SA (2004)
10.3171/jns.2005.102.2.0363 / Neurosurg-. by FARHADI MR (2005)

Dates

Type	When
Created	20 years, 1 month ago (July 14, 2005, 6:03 a.m.)
Deposited	6 years, 6 months ago (March 6, 2019, 5:58 a.m.)
Indexed	1 month ago (Aug. 2, 2025, 1 a.m.)
Issued	20 years, 2 months ago (July 1, 2005)
Published	20 years, 2 months ago (July 1, 2005)
Published Online	20 years, 1 month ago (July 14, 2005)
Published Print	20 years, 2 months ago (July 1, 2005)

Funders 0

None

BibTeX

@article{Doggrell_2005, title={Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration: GRAGOUNDAS ES, ADAMIS AP, CUNNINGHAM ETet al.: Pegaptanib for neovascular age-related macular degeneration.N. Engl. J. Med.(2004) 351:2805-2816.}, volume={6}, ISSN={1744-7666}, url={http://dx.doi.org/10.1517/14656566.6.8.1421}, DOI={10.1517/14656566.6.8.1421}, number={8}, journal={Expert Opinion on Pharmacotherapy}, publisher={Informa Healthcare}, author={Doggrell, Sheila A}, year={2005}, month=jul, pages={1421–1423} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2025,
        8,
        2
      ]
    ],
    "date-time": "2025-08-02T05:00:25Z",
    "timestamp": 1754110825415
  },
  "reference-count": 5,
  "publisher": "Informa Healthcare",
  "issue": "8",
  "content-domain": {
    "domain": [],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2005,
        7
      ]
    ]
  },
  "DOI": "10.1517/14656566.6.8.1421",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2005,
        7,
        14
      ]
    ],
    "date-time": "2005-07-14T10:03:16Z",
    "timestamp": 1121335396000
  },
  "page": "1421-1423",
  "source": "Crossref",
  "is-referenced-by-count": 69,
  "title": "Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration",
  "prefix": "10.1517",
  "volume": "6",
  "author": [
    {
      "given": "Sheila A",
      "family": "Doggrell",
      "sequence": "first",
      "affiliation": []
    }
  ],
  "member": "3197",
  "published-online": {
    "date-parts": [
      [
        2005,
        7,
        14
      ]
    ]
  },
  "reference": [
    {
      "key": "CIT0001",
      "doi-asserted-by": "crossref",
      "first-page": "1509",
      "DOI": "10.1001/jama.293.12.1509",
      "volume": "293",
      "author": "VAN WIJINGARDEN P",
      "year": "2005",
      "journal-title": "JAMA"
    },
    {
      "key": "CIT0002",
      "doi-asserted-by": "crossref",
      "first-page": "20556",
      "DOI": "10.1074/jbc.273.32.20556",
      "volume": "32",
      "author": "RUCKMAN J",
      "year": "1998",
      "journal-title": "J. Biol. Chem."
    },
    {
      "key": "CIT0003",
      "first-page": "2805",
      "volume": "351",
      "author": "GRAGOUNDAS ES",
      "year": "2004",
      "journal-title": "Pegaptanib for neovascular age-related macular degeneration. N Engl. J. Med."
    },
    {
      "key": "CIT0004",
      "first-page": "2621",
      "volume": "5",
      "author": "DOGGRELL SA",
      "year": "2004",
      "journal-title": "Pharmacother."
    },
    {
      "key": "CIT0005",
      "doi-asserted-by": "crossref",
      "first-page": "363",
      "DOI": "10.3171/jns.2005.102.2.0363",
      "volume": "102",
      "author": "FARHADI MR",
      "year": "2005",
      "journal-title": "Neurosurg-."
    }
  ],
  "container-title": "Expert Opinion on Pharmacotherapy",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "http://www.tandfonline.com/doi/pdf/10.1517/14656566.6.8.1421",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2019,
        3,
        6
      ]
    ],
    "date-time": "2019-03-06T10:58:48Z",
    "timestamp": 1551869928000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "http://www.tandfonline.com/doi/full/10.1517/14656566.6.8.1421"
    }
  },
  "subtitle": [
    "GRAGOUNDAS ES, ADAMIS AP, CUNNINGHAM ET<i>et al.</i>: Pegaptanib for neovascular age-related macular degeneration.<i>N. Engl. J. Med.</i>(2004) 351:2805-2816."
  ],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2005,
        7
      ]
    ]
  },
  "references-count": 5,
  "journal-issue": {
    "issue": "8",
    "published-online": {
      "date-parts": [
        [
          2005,
          7,
          14
        ]
      ]
    },
    "published-print": {
      "date-parts": [
        [
          2005,
          7
        ]
      ]
    }
  },
  "alternative-id": [
    "10.1517/14656566.6.8.1421"
  ],
  "URL": "http://dx.doi.org/10.1517/14656566.6.8.1421",
  "relation": {},
  "ISSN": [
    "1465-6566",
    "1744-7666"
  ],
  "subject": [],
  "container-title-short": "Expert Opinion on Pharmacotherapy",
  "published": {
    "date-parts": [
      [
        2005,
        7
      ]
    ]
  }
}